JP2022554019A - 補体成分C5a受容体の遊離塩基結晶形態 - Google Patents

補体成分C5a受容体の遊離塩基結晶形態 Download PDF

Info

Publication number
JP2022554019A
JP2022554019A JP2022525889A JP2022525889A JP2022554019A JP 2022554019 A JP2022554019 A JP 2022554019A JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022554019 A JP2022554019 A JP 2022554019A
Authority
JP
Japan
Prior art keywords
disease
free base
crystalline form
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022525889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554019A5 (cg-RX-API-DMAC7.html
Inventor
シン ラジンダー
ヤウ クウォク
イーピン ツォン
ジャーン ペングリー
エム.ルイ レベッカ
クラシンスキ アントニ
Original Assignee
ケモセントリックス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス,インコーポレイティド filed Critical ケモセントリックス,インコーポレイティド
Publication of JP2022554019A publication Critical patent/JP2022554019A/ja
Publication of JP2022554019A5 publication Critical patent/JP2022554019A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Medical Uses (AREA)
JP2022525889A 2019-11-08 2020-11-06 補体成分C5a受容体の遊離塩基結晶形態 Withdrawn JP2022554019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932652P 2019-11-08 2019-11-08
US62/932,652 2019-11-08
PCT/US2020/059287 WO2021092292A1 (en) 2019-11-08 2020-11-06 FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR

Publications (2)

Publication Number Publication Date
JP2022554019A true JP2022554019A (ja) 2022-12-27
JP2022554019A5 JP2022554019A5 (cg-RX-API-DMAC7.html) 2023-11-09

Family

ID=75846182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525889A Withdrawn JP2022554019A (ja) 2019-11-08 2020-11-06 補体成分C5a受容体の遊離塩基結晶形態

Country Status (13)

Country Link
US (3) US11026935B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022554019A (cg-RX-API-DMAC7.html)
KR (1) KR20220098179A (cg-RX-API-DMAC7.html)
CN (1) CN114641289A (cg-RX-API-DMAC7.html)
AU (1) AU2020378061A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007488A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155596A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001173A1 (cg-RX-API-DMAC7.html)
IL (1) IL292317A (cg-RX-API-DMAC7.html)
MX (1) MX2022005403A (cg-RX-API-DMAC7.html)
WO (1) WO2021092292A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305622B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380367B2 (en) 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
US20260027049A1 (en) 2024-07-23 2026-01-29 Amgen Inc. Avacopan formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
JP5819730B2 (ja) * 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト製造における方法及び中間体
AU2020380367B2 (en) * 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Also Published As

Publication number Publication date
IL292317A (en) 2022-06-01
CL2022001173A1 (es) 2023-02-10
EP4054577A1 (en) 2022-09-14
MX2022005403A (es) 2022-05-24
BR112022007488A2 (pt) 2022-07-12
CN114641289A (zh) 2022-06-17
CA3155596A1 (en) 2021-05-14
ZA202305622B (en) 2024-01-31
WO2021092292A1 (en) 2021-05-14
EP4054577A4 (en) 2023-11-29
US20220096453A1 (en) 2022-03-31
KR20220098179A (ko) 2022-07-11
AU2020378061A1 (en) 2022-05-26
US20210137907A1 (en) 2021-05-13
US20230381167A1 (en) 2023-11-30
US11026935B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
US20230381167A1 (en) FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
US20200262853A1 (en) SOLUBLE C5aR ANTAGONISTS
US11603356B2 (en) Amorphous form of a complement component C5a receptor
TWI900501B (zh) 補體成分C5a受體之鹽形式
RU2859662C2 (ru) АМОРФНАЯ ФОРМА КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a
RU2859117C1 (ru) СОЛЕВЫЕ ФОРМЫ КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231031

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240524